BCL2L12 and ovarian carcinoma: BUD31 overexpression drives an oncogenic splicing switch in BCL2L12 to produce full-length BCL2L12 that in turn confers cancer cells resistance to apoptosis promotes the proliferation of ovarian cancer cells.